Coya Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies that enhance the function of regulatory T cells (Tregs) in vivo. It is focused on creating proprietary medicinal products, including allogeneic Treg-derived exosome therapeutics and novel biologics. The company aims to address various medical conditions, including neurodegenerative, autoimmune, and metabolic diseases, through its multi-modality Treg therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.